Register Now
Course Information

Agenda

Monday      Tuesday      Wednesday      Thursday     

Monday, November 29, 2021

8:30 am
Welcome and Introductions
Daniel Culver, DO, Co-Activity Director
Manuel Ribeiro Neto, MD, Co-Activity Director


Session Chairs: Wim Wuyts, MD, PhD and Brian Southern, MD
8:35 am
Progressive Fibrosis: Lumping, Splitting, Both or Neither
Athol Wells, MD
8:55 am
Innate Immune Mechanisms in Fibrotic Lung Disease
Bethany Moore, PhD
9:15 am
Role of Lymphocytes in Pulmonary Fibrosis
Catherine Bonham, MD
9:35 am
New Findings in the Genetics of Fibrosis in African Americans
Courtney Gray Montgomery, PhD
9:55 am
Metabolic Mediators of Fibrosis
Victor Thannickal, MD
10:15 am
Exhibit Break
10:40 am
Intersection between Fibrosis and Inflammation
Elizabeth Redente, PhD
11:00 am
Mechanisms of Granulomatous Fibrosis
Denise Kirschner, PhD
11:20 am
Predicting Outcomes in Fibrotic ILD
Justin Oldham, MD
11:40 am
Panel Discussion - All Session Faculty
12:00 pm
Lunch Break / Networking Lounge

Session Chairs: Antje Prasse, MD, and Laura Koth, MD
12:45 pm
Innate Immune Mechanisms in Sarcoidosis
Thomas Weichhart, MD
1:05 pm
Identifying an Etiologic Trigger for Sarcoidosis
Andrew Fontenot, MD
1:25 pm
Pro/Con: Funding Agencies Should Concentrate on Funding for a Specific Etiology
Pro - Wonder Drake, MD
Con - Elliott Crouser, MD
1:55 pm
Panel Discussion - All Session Faculty
2:15 pm
Adjourn

Back to top

Tuesday, November 30, 2021

8:25 am
Welcome and Introductions
Daniel Culver, DO, Co-Activity Director
Manuel Ribeiro Neto, MD, Co-Activity Director


Session Chairs: Kristin Highland, MD, and Martin Kolb, MD, PhD
8:30 am
Pulmonary Vasculature in ILD: Bystander or Culprit
Bruno Crestani, MD
8:45 am
Angiogenesis in Fibrosis
Maximillian Ackermann, MD
9:00 am
Vascular-parenchymal Relationships in Fibrotic Lung Disease
Toyoshi Yanagihara, MD
9:15 am
Therapies for Pulmonary Hypertension in ILD
Steven Nathan, MD
9:30 am
Panel Discussion - All session faculty
9:50 am
Exhibit Break

Session Chairs: Robert Baughman, MD, and Hilario Nunes, MD, PhD
10:10 am
Epidemiology and Natural Course of SAPH
Oksana Shlobin, MD
10:25 am
Screening and Diagnosis of SAPH
Marloes Huitema, MD
10:40 am
Treatment Principles for SAPH
Laurent Savale, MD
10:55 am
Riociguat for SAPH: Results of Double Blind Placebo Controlled Trial
Rohit Gupta, MD
11:10 am
Panel Discussion – All session faculty
11:30 am
Break

Session Chairs: Karen Patterson, MD, and Remy Mostard, MD, PhD
11:40 am
Chest CT as a Basis of Integrative Biomarkers in Sarcoidosis
Lisa Maier, MD, MSPH
11:55 am
CT Phenotypes in Sarcoidosis; Results of a Delphi Project
Nishanth Sivarasan, MBBS
12:10 pm
Artificial Intelligence and Deep Learning Approaches for Imaging ILD
12:25 pm
Deep Learning for Quantification
Stephen Humphries, PhD
12:40 pm
Clinical Context for Quantitative Imaging: Will It Help Manage My Patient?
Jan Grutters, MD, PhD
12:55 pm
Panel Discussion - All Session Faculty
1:15 pm
Adjourn

Back to top

Wednesday, December 1, 2021

8:25 am
Welcome and Introductions
Daniel Culver, DO, Co-Activity Director
Manuel Ribeiro Neto, MD, Co-Activity Director

Session Chairs: Marlies Wijsenbeek, MD, and Ennis James, MD
8:30 am
ERS Treatment Guidelines Overview
Dominique Valeyre, MD
8:45 am
Are the ERS Guidelines Helpful?
Marc Judson, MD
9:00 am
Pro/Con: Most Patients with Progressive Fibrotic Sarcoidosis Should Receive Antifibrotics
Pro – Athol Wells, MD
Con - Faculty TBA
9:30 am
Current Treatment Landscape Discussion - All Session Faculty
9:50 am
Exhibit Break

Session Chairs: Francesco Bonella, MD, PhD, and Alicia Gerke, MD, MBA
10:15 am
Trials: Abasarc
Björn Frye, MD
10:30 am
Trials: Pirfenidone for fibrotic pulmonary sarcoidosis
Robert Baughman, MD
10:45 am
Trials: aTyr
Ennis James, MD
11:00 am
Thoughts on Clinical Trial Design in Sarcoidosis
Daniel Culver, DO
11:15 am
Panel Discussion - All Session Faculty
11:30 am
Exhibit Break

Session Chairs: Paolo Spagnolo, MD, PhD, and Nabeel Hamzeh, MD
11:50 am
Pro/Con: PET Scan Should be Adopted as a Routine Tool for Sarcoidosis Management and Clinical Trials
Pro – Robert Baughman, MD
Con – Marc Judson, MD
12:20 pm
Genes and Environment are Key Determinants of Sarcoidosis
Natalia Rivera, MD
12:35 pm
Socioeconomic Determinants and Disparities in Sarcoidosis
Michelle Sharp, MD, MHS
12:50 pm
Panel Discussion - All Session Faculty
1:15 pm
Adjourn

Back to top

Thursday, December 2, 2021

8:25 am
Welcome and Introductions
Daniel Culver, DO, Co-Activity Director
Manuel Ribeiro Neto, MD, Co-Activity Director

Session Chairs: Marcel Veltkamp, MD, PhD, and Manuel Ribeiro Neto, MD
8:30 am
Update on Arrhythmias in CS
Jordana Kron, MD
8:45 am
Risk Stratification for Sudden Cardiac Death; Known Knowns and Known Unknowns
9:00 am
Immunosuppressive Therapy for CS: Who and How to Treat and for How Long?
Manuel Ribeiro Neto, MD
9:15 am
Immunomodulation for Prevention of Myocardial Fibrosis
Carsten Tschöpe, MD
9:30 am
Panel Discussion - All Session Faculty
9:50 am
Break / Networking Lounge

Session Chairs: David Birnie, MD, and Christine Jellis, MD, PhD
10:15 am
Screening for Cardiac Sarcoidosis: In Whom, When, and How?
Vasilis Kouranos, MD, PhD
10:30 am
MRI Imaging of Cardiac Sarcoidosis: Indications, Techniques, Pitfalls and Future Directions
Chetan Shenoy, MBBS
10:45 am
FDG-PET Imaging of CS: Indications, Techniques, Pitfalls, Recent Guidelines, and Future Directions
Ron Blankstein, MD
11:00 am
Panel Discussion - All Session Faculty
11:20 am
Exhibit Break

Session Chairs: Ziad Taimeh, MD, and Divya Patel, DO
11:45 am
Pro/Con: All Patients with CS Should Receive an ICD
12:10 pm
Pro/Con: Is Isolated Cardiac Sarcoidosis an Important Diagnosis?
Pro: Leslie Cooper, Jr., MD
Con: David Birnie, MD
12:35 pm
My Nightmare CS Case: Difficult Case Management for Discussion
Daniel Culver, DO
David Birnie, MD
Ron Blankstein, MD
Vasilis Kouranos, MD, PhD
Rakesh Sharma, MBBS, PhD
Manuel Ribeiro Neto, MD, Moderator
1:15 pm
Panel Discussion - All Daily Faculty
1:45 pm
Closing Remarks and Adjourn

Back to top